Drug Discovery Informatics Market - Global Industry Analysis

Drug Discovery Informatics Market (Outsourced Informatics; In-House Informatics & Off-Premise Outsourced Informatics And Services) For Docking, Enterprises (Small, Mid And Large-Size Enterprises) And Law Firms - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends And Forecast, 2020 – 2028

Published Date: 07-Jun-2021 Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-40 Status : Published

Global Drug Discovery Informatics Market accounted for USD 4.12 Billion in 2020 and is expected to reach USD 8.17 Billion by 2028, growing at a CAGR of around 8.9% between 2021 and 2028.

Description

Market Overview     

The global Drug Discovery Informatics Market accounted for USD 4.12 Billion in 2020 and is expected to reach USD 8.17 Billion by 2028, growing at a CAGR of around 8.9% between 2021 and 2028.

The drug discovery informatics market is about to realize momentum within the coming years owing to advancements in high-performance computing & web services, the growing volume of drug discovery data, the growing adoption of in-silico modeling tools, and the increasing demand for novel medicine moieties. The launch of advanced drug discovery information technology is about to accentuate the industry competition. For Instance, in January 2021, Certara, Inc. launched Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform version 20. The new models help in analyzing and assessing the drug action during lactation and pregnancy.

In addition, it helps the purchasers with critical decisions regarding optimizing medication safety and efficacy profile. Companies also are increasingly adopting informatics solutions to shorten the long drug discovery timeline. as an example, in December 2020, Curve Therapeutics Ltd. implemented the CDD Vault platform for handling its genetically encoded Microcycle platform. it's a ubiquitous hosted platform suitable for applications across, biotechnology, pharmaceutical & academic institutes for securing and seamless sharing of knowledge in real-time, thereby facilitating collaborative discoveries.

COVID-19 Impact Analysis  

The impact of COVID-19 is supposed to be for a short-range; however, its impact going to have a vast effect on the drug discovery companies, forecast to a big scope for a minimum of a year to 12-15 months. This led to organizations capitalizing more on solutions and services to endure operations. Governments are declaring packages to assist businesses during this pandemic, with a special specialization in Small & Medium-scale Enterprises. Besides, the accelerated Covid-19 drug discovery around the world is supplementarily contributing to the market growth. For instance, providing fast-track solutions, scientists executed virtual screening using medicine from the DrugBank, for targeting the viral proteins and human ACE2 receptors. These studies were supported in silico tools for screening small molecules that have the likely usage in drug discoveries against Covid-19.

Companies are also developing several web services & solutions for supporting various steps of drug development for Covid-19. For example, in June 2020, the IBM visual molecular explorer platform explored a specific set of the generated molecules targeting the coronavirus (SARS-CoV-2). The open-source sharing of the AI-generated artifacts within the explorer helped within the initial stages of optimal medicine designing.

Growth Factors

Market growth is essentially driven by factors like the increasing R&D expenditure, budding support for research, particularly within the area of rare diseases, and therefore the growing use of informatics in drug discovery. Players across the drug discovery informatics market are concentrating aggressively on innovation, also on including advanced technologies in their existing products. Over the approaching years, they're also expected to require up partnerships and mergers & acquisitions as their key strategy for business development. However, the scarcity of expert professionals and so the high setup cost of informatics Outsourced Informatics is anticipated to limit market growth to a particular extent.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

 

Mode Segment Analysis Preview  

The outsourced segment will expand further at a gentle CAGR during the forecast period on account of an increasing number of partnerships between pharmaceutical companies & contract development and manufacturing organizations. Contract Research Organizations are involved in the creation of reports on new drug entities that are subsequently employed by the drug manufacturer/sponsor for submitting to the U.S. FDA. There are benefits when pharmaceutical & biotechnology companies partner with a CRO that has an equivalent informatics solution. The shared informatics platform between the CRO and corporations helps in monitoring the progress of studies in the same way as their internal studies. This helps the corporate in cost-saving and productivity gain, which is predicted to supply the market entities immense profitable opportunities.

Service Segment Analysis Preview  

The informatics platform enables users to rearrange peptide sequences supported by code by property. Molecular modeling is progressively gaining popularity due to its wide application within the drug discovery process. These tools are applied for the modeling & simulation of biological systems and little molecules for understanding & forecasting their behavior at a molecular level. Additionally, they accelerate the cost-efficiency of hit discovery and hit-to-lead optimization.

Regional Segment Analysis Preview  

Globally, North America has been leading the worldwide drug discovery informatics market and is expected to continue on the dominant position within the years to return, followed by Europe. Growing penetration of in-silico technologies also their rampant use witnessed within the region is that the key factor behind the dominance of the North American drug discovery informatics market. The high number of market players being headquartered in North America is another significant factor that's supporting this regional market. APAC drug discovery informatics market is expected to witness swift growth, due to the growing presence of pharmaceutical firms alongside the increasing occurrence of cancer ailment in most populated countries like India and China.

Key Market Players & Competitive Landscape

The key players profiled in the report include Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., Illumina, Inc. and amongst others.

The global Drug Discovery Informatics is segmented as follows:

By Mode

  • Outsourced Informatics
  • In-House Informatics

By Services

  • Docking
  • Modular Modeling

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Mode
        • 2.1.1.2. Market Attractiveness Analysis, By Service
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Drug Discovery Informatics, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Drug Discovery Informatics – Component Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Mode, 2020 & 2028
    • 4.2. Outsourced Informatics
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. In-House Informatics
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Drug Discovery Informatics – Service Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Service, 2020 & 2028
    • 5.2. Docking
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Modular Modeling
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Drug Discovery Informatics – Region Segment Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Mode, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Service, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Mode, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By Service, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Mode, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By Service, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Mode, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By Service, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Mode, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Service, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Mode, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By Service, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Mode, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By Service, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Mode, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By Service, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Mode, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By Service, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Mode, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By Service, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Mode, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By Service, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Mode, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Service, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Mode, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By Service, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Mode, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By Service, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Mode, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By Service, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Mode, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By Service, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Mode, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By Service, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Mode, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Service, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Mode, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Service, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Mode, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By Service, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Mode, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By Service, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Mode, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By Service, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Mode, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Service, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Mode, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By Service, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Mode, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By Service, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Mode, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Service, 2016 – 2028
  • Chapter No. 7: Drug Discovery Informatics – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. Technology Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Drug Discovery Informatics: Company Market Share, 2019
      • 8.1.2. Global Drug Discovery Informatics, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 8.1.3. Global Drug Discovery Informatics, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Drug Discovery Informatics: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Certara
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
    • 9.2 Certara
    • 9.3 Boehringer Ingelheim International GmbH
    • 9.4 Infosys Ltd.
    • 9.5 Charles River Laboratories
    • 9.6 Cullaborative Drug Discovery, Inc.
    • 9.7 Eurofins DiscoverX Products
    • 9.8 Jubilant Biosys
    • 9.9 Selvita
    • 9.10 Novo Informatics Pvt. Ltd.
    • 9.11 ChemAxon Ltd.
    • 9.12 Albany Mulecular Research Inc.
    • 9.13 Oracle
    • 9.14 Accenture
    • 9.15 Agilent Technulogies, Inc.
  • Chapter No. 11: Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

Table Of Figures

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Mode
FIG NO. 2. Market Attractiveness Analysis, By Service
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global Drug Discovery Informatics Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Mode, 2020 & 2028 
FIG NO. 7. Global Drug Discovery Informatics for Outsourced Informatics, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of Drug Discovery Informatics for Outsourced Informatics, By Country, 2020 & 2028
FIG NO. 9. Global Drug Discovery Informatics for In-House Informatics, Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Drug Discovery Informatics for In-House Informatics, By Country, 2020 & 2028
FIG NO. 11. Market Revenue Share, By Service, 2020 & 2028
FIG NO. 12. Global Drug Discovery Informatics for Docking, Revenue (USD Billion) 2016 – 2028
FIG NO. 13. Comparative Revenue Analysis of Drug Discovery Informatics for Docking, By Country, 2020 & 2028 
FIG NO. 14. Global Drug Discovery Informatics for Modular Modeling, Revenue (USD Billion) 2016 – 2028
FIG NO. 15. Comparative Revenue Analysis of Drug Discovery Informatics for Modular Modeling, By Country, 2020 & 2028
FIG NO. 16. Global Drug Discovery Informatics Revenue Share, By Region, 2020 & 2028
FIG NO. 17. North America Drug Discovery Informatics Revenue, 2016 - 2028 (USD Billion)
FIG NO. 18. Porter’s Five Forces Analysis for Global Drug Discovery Informatics
FIG NO. 19. PEST Analysis for Global Drug Discovery Informatics
FIG NO. 20. Pricing Analysis for Global Drug Discovery Informatics
FIG NO. 21. Value Chain Analysis for Global Drug Discovery Informatics
FIG NO. 22. Company Share Analysis, 2019
FIG NO. 23. Radar Determinant Chart, 2019
FIG NO. 24. Company Strategic Developments – Heat Map Analysis
FIG NO. 25. Royal DSM Company Business Segment Revenue Share, 2020 (%)
FIG NO. 26. Royal DSM  Company Geographical Segment Revenue Share, 2020 (%)
FIG NO. 27. Market Channels
FIG NO. 28. Marketing Channel Development Trend
FIG NO. 29. Growth in World Gross Product, 2008-2018
FIG NO. 30. Research Methodology – Detailed View
FIG NO. 31. Research Methodology


Table Of Tables

List of Tables 

TABLE NO. 1. Global Drug Discovery Informatics: Snapshot
TABLE NO. 2. Quarterly Drug Discovery Informatics Revenue by Region, 2020
TABLE NO. 3. Quarterly Drug Discovery Informatics Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion) 
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion) 
TABLE NO. 6. Global Drug Discovery Informatics for Outsourced Informatics, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Drug Discovery Informatics for In-House Informatics, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Drug Discovery Informatics for Docking, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9 Global Drug Discovery Informatics for Modular Modeling, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10 Global Drug Discovery Informatics Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. North America Drug Discovery Informatics Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 12. North America Drug Discovery Informatics Revenue, By Mode, 2016 – 2028 (USD Billion)
TABLE NO. 13. North America Drug Discovery Informatics Revenue, By Service, 2016 – 2028 (USD Billion)
TABLE NO. 14. U.S. Drug Discovery Informatics Revenue, By Mode, 2016 – 2028 (USD Billion)
TABLE NO. 15. U.S. Drug Discovery Informatics Revenue, By Service, 2016 – 2028 (USD Billion)
TABLE NO. 16. Canada Drug Discovery Informatics Revenue, By Mode, 2016 – 2028 (USD Billion)
TABLE NO. 17. Canada Drug Discovery Informatics Revenue, By Service, 2016 – 2028 (USD Billion)
TABLE NO. 18. Mexico Drug Discovery Informatics Revenue, By Mode, 2016 – 2028 (USD Billion)
TABLE NO. 19. Mexico Drug Discovery Informatics Revenue, By Service, 2016 – 2028 (USD Billion)
TABLE NO. 20. Drivers for the Drug Discovery Informatics: Impact Analysis
TABLE NO. 21. Restraints for the Drug Discovery Informatics: Impact Analysis
TABLE NO. 22. Major Buyers of Aquaculture
TABLE NO. 23. Distributors/Traders List of Aquaculture
TABLE NO. 24. Global Drug Discovery Informatics, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 25: Global Drug Discovery Informatics, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)   


 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Drug Discovery Informatics market. Zion Research has collected and analyzed key data belong to the global Drug Discovery Informatics market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducing a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Drug Discovery Informatics across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Drug Discovery Informatics industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Drug Discovery Informatics market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Drug discovery is a havoc process that requires much time to invent the drug for any disease or disorder. During the invention procedure, it generates the huge amount of data which can be further utilized while clinical study or other during other invention. This data can be stored manipulate and retrieve through the drug discovery analytics.

Drug discovery analytics is a special kind of application or software which can be stores and retrieves the structured and unstructured data that is generated while drug discovery process. The drug discovery analytics helps to reduce the cost of treatment and it provides efficient and accurate data. This kind of data is utilized further by R&D, pharmaceutical, biotech companies and physicians. 

The drug discovery informatics market is primarily driven by rising demand for computational technology in the medical industry. Use of computational technology offers the fastest and accurate data to the end-users. However, critical attributes of data evaluation in drug discovery informatics is a major restraint that is likely to impede the growth of the market. Nonetheless, adoption of computational technology in emerging economies is expected to open new opportunities for market participants in near future.

Based on mode, the global drug discovery informatics market is segmented into outsourced informatics and in-house informatics. Among two, in-house informatics was leading mode segment. It accounted more than 50.0% share of the overall revenue generated by global drug discovery informatics market in 2015.  Moreover, the outsourced informatics is expected to have significant growth during the years to come.

Docking, modular modeling, and others are the key services of global drug discovery informatics market. Modular modeling was the foremost service segment that accounted for over 22.0% share of the entire market in 2015. Furthermore, it also expected to grow at a moderate pace due to growing adoption of analytics in the medical industry across the globe.

With the largest share, North America was the dominating regional market for drug discovery informatics in 2015. Asia Pacific is foreseen as a fastest growing region for drug discovery informatics market due to emerging pharmaceutical industries coupled with rising prevalence of cancer disease in China and India. Furthermore, Europe is likely to witness a moderate growth within the forecast period.

Some of the key players involved in global drug discovery informatics market include ChemAxon, GVK Biosciences, Jubilant Biosys, Selvita, Certara, Infosys, Albany Molecular Research Inc., Boehringer Ingelheim GmBh, DiscoverX, Charles River Laboratories, Covance, Collaborative Drug Discovery Inc., Novo Informatics, UCB, Evotec among others.

Choose License Type

FrequentlyAsked Questions

The global Drug Discovery Informatics was valued at USD 4.12 Billion in 2020.

The global Drug Discovery Informatics is expected to reach USD 8.17 Billion by 2028, growing at a CAGR of 8.9% between 2021 to 2028.

Escalating demand for quick data access and the rising need for minimizing costs of drug discovery as a result of easy availability of information will spur the drug discovery informatics market.

North America is the largest market for drug discovery informatics in the world. Out of all the 50 states in the country, 49 states have already enacted e-discovery rules.  The large share of North America in the global market can be attributed to the presence of well-established CROs, increasing R&D expenditure by pharmaceutical and biopharmaceutical companies.

Key manufacturers included in the study are ertara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., Illumina, Inc. and amongst others.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed